Retatrutide Side Effects: Complete Guide to Clinical Trial Safety Data

Introduction

Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist being developed by Eli Lilly. It has been studied in Phase 1, Phase 2 and now Phase 3 clinical trials. The Phase 3 TRIUMPH-4 results (December 2025) greatly expanded the safety database and revealed a new finding, dysesthesia, not seen in earlier trials. TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3 (80 weeks each) reported in 2026 with lower dysesthesia rates at 12 mg (12.5%, 7.3% and 6.4%); their full safety tables are on the TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3 pages. This page concentrates on the Phase 2 and TRIUMPH-4 data.

We look at side effects reported across published retatrutide trials, focusing on the Phase 2 obesity trial (New England Journal of Medicine), the Phase 2 type 2 diabetes trial (The Lancet) and the Phase 3 TRIUMPH-4 trial. Because retatrutide is still investigational, all side effect data here come from controlled clinical trials and may not fully match what happens in wider clinical practice.

Gastrointestinal Side Effects

The Dominant Category

Gastrointestinal (GI) side effects are the most common with retatrutide, as with every incretin-based drug. Retatrutide’s GLP-1 component activates receptors in the gut and brainstem that slow stomach emptying, reduce bowel movement and trigger nausea through the area postrema. These effects are predictable from how the drug works and are closely tied to the appetite suppression that drives weight loss.

GI Side Effects by Dose Level (Phase 2 Obesity Trial)

The Phase 2 obesity trial (Jastreboff et al., NEJM 2023, Table 3; 48 weeks) reported GI events for each group. “Start” is the first weekly dose before stepping up:

Adverse Event	Placebo (n=70)	1 mg (n=69)	4 mg, 2 mg start (n=33)	4 mg, 4 mg start (n=33)	8 mg, 2 mg start (n=35)	8 mg, 4 mg start (n=35)	12 mg, 2 mg start (n=62)
Nausea	11%	14%	18%	36%	17%	60%	45%
Vomiting	1%	3%	12%	12%	6%	26%	19%
Diarrhea	11%	9%	12%	12%	20%	20%	15%
Constipation	3%	7%	15%	6%	11%	11%	16%
Decreased appetite	9%	13%	18%	24%	11%	31%	29%

GI events were more common at higher doses, and starting at 4 mg rather than 2 mg raised them further. The groups were small, so the pattern from one dose to the next is not perfectly even.

Nausea

Nausea was the most commonly reported side effect across retatrutide trials. Key points:

• Timing: Most nausea happened during dose escalation, usually in the first 8 to 12 weeks, and eased a lot once participants reached their maintenance dose
• Severity: The vast majority of nausea episodes were mild to moderate. Severe GI adverse events of any kind were reported in 2% of all Phase 2 participants (4 of 62, or 6%, in the 12 mg group)
• Persistence: Nausea was usually temporary, lasting hours to days rather than being constant
• Discontinuation: Nausea led 4 of 337 Phase 2 participants (1%) to stop treatment

Vomiting

Vomiting was the second most disruptive GI side effect. In the Phase 2 obesity trial it occurred in 3% to 26% of retatrutide groups (19% at 12 mg) and 1% on placebo. Vomiting tended to come with nausea, clustered early in treatment during dose escalation, and was mostly mild to moderate. Vomiting rates with retatrutide are broadly similar to those of other GLP-1 receptor agonists at effective doses.

Diarrhea

In the Phase 2 obesity trial, diarrhea was reported in 9% to 20% of retatrutide groups (15% at 12 mg), compared with 11% on placebo. In TRIUMPH-4 it was more common: 33.1% at 12 mg versus 13.4% on placebo. It was most noticeable during escalation. Most episodes were temporary and cleared up without treatment. Retatrutide’s glucagon component may add to diarrhea by affecting fluid secretion and movement in the gut.

Constipation and Dyspepsia

Constipation was reported in 6% to 16% of retatrutide groups in the Phase 2 obesity trial (3% on placebo), probably because GLP-1 receptor agonism slows gut movement. Dyspepsia (indigestion) and abdominal discomfort also occurred, though less often. Constipation and diarrhea rarely occurred in the same person; different participants had different GI effects depending on their own physiology.

Decreased Appetite

Decreased appetite was reported often across treatment groups. It is both an intended drug effect and a recorded adverse event. Rates rose with dose and tracked the amount of weight lost. It shows the drug is engaging the central appetite pathways controlled by GLP-1 and GIP receptors in the hypothalamus and brainstem.

Comparison to Placebo

This table summarizes the overall adverse event picture from the Phase 2 obesity trial and shows the clear gap between active treatment and placebo:

Category	Placebo (n=70)	Retatrutide 12 mg (n=62)
Any adverse event	70%	92%
Serious adverse events	4%	3%
Discontinuation due to AEs	0%	16%
Injection-site reaction	0%	8%

The higher overall adverse event rate with retatrutide comes mainly from GI events. Serious adverse events were uncommon (4% in both the placebo and the combined retatrutide groups) and not clearly linked to dose. At 12 mg, 16% of participants stopped treatment because of side effects, against none on placebo.

The Role of Dose Escalation

Why Titration Matters

One of the most important Phase 2 findings was how much the escalation strategy affected tolerability. The Phase 2 obesity trial had two 4 mg arms and two 8 mg arms, one of each starting at 2 mg and one starting at 4 mg, which allowed a direct comparison (Table 3 of the NEJM paper):

Parameter	4 mg, 4 mg start	4 mg, 2 mg start	8 mg, 4 mg start	8 mg, 2 mg start
Nausea	36%	18%	60%	17%
Vomiting	12%	12%	26%	6%
Discontinuation due to AEs	9%	6%	6%	14%

Starting at 4 mg doubled nausea in the 4 mg arms and more than tripled it in the 8 mg arms. Discontinuation did not follow the same pattern, and each arm had only 33 to 35 people, so those figures are less certain.

Escalation Protocol

In the escalation arms, participants began at 2 mg and increased every four weeks. Going slowly lets the body adapt to incretin receptor activation, and GI side effects ease at each dose level before the next increase. In Phase 2 the 12 mg group stepped through 2 mg, 4 mg and 8 mg before reaching 12 mg; the Phase 3 schedule adds a 6 mg step (2 → 4 → 6 → 9 → 12 mg) and reaches 12 mg at week 17.

Clinical Implications of Dose Escalation

The escalation data have useful practical lessons:

• Tolerability can be changed: The side effect burden is not fixed by the drug. It depends a lot on how fast the dose goes up
• Patience with titration pays off: A lower starting dose cut nausea and, in the 8 mg arms, vomiting
• Doses can be adjusted for each person: In practice, escalation can be slowed or paused for patients with significant GI symptoms, as is common with other incretin drugs

TRIUMPH-4 Phase 3 Safety Data

New Finding: Dysesthesia

The most important safety finding from TRIUMPH-4 was dysesthesia, a sensory nerve disturbance that causes abnormal sensations such as numbness, tingling, burning or prickling. In the smaller Phase 2 obesity trial, related skin-sensation events (hyperesthesia and similar terms) had been reported in 7% of retatrutide participants and 1% on placebo. TRIUMPH-4 reported:

Parameter	Placebo	Retatrutide 9 mg	Retatrutide 12 mg
Dysesthesia incidence	0.7%	~8.8%	20.9%

This sets retatrutide apart from other incretin-based drugs, none of which have shown similar dysesthesia rates. The cause is under investigation. Possible explanations include:

• Direct effects on sensory nerve function through one of the three receptor targets
• Indirect effects related to rapid metabolic changes (such as rapid weight loss or fat redistribution)
• Nutritional deficiency secondary to reduced food intake

The later TRIUMPH trials reported lower rates at 12 mg (12.5% in TRIUMPH-1, 7.3% in TRIUMPH-2, 6.4% in TRIUMPH-3). Whether dysesthesia is mild and short-lived, or persistent and troublesome, is still being worked out.

GI Tolerability in TRIUMPH-4

TRIUMPH-4 gave the first detailed Phase 3 GI side effect data for retatrutide, over 68 weeks of treatment:

Adverse Event	Placebo	Retatrutide 9 mg	Retatrutide 12 mg
Nausea	10.7%	38.1%	43.2%
Diarrhea	13.4%	34.7%	33.1%
Vomiting	0.0%	20.4%	20.9%
Constipation	8.7%	21.8%	25.0%
Decreased appetite	9.4%	19.0%	18.2%

A few things stand out. At 12 mg, nausea (43.2% vs 45%) and vomiting (20.9% vs 19%) were similar to the Phase 2 obesity trial, while diarrhea (33.1% vs 15%) and constipation (25.0% vs 16%) were more common. The trials differ in length (68 versus 48 weeks), population and escalation schedule. Nausea is still the most common GI event, as expected from GLP-1 receptor activation. The fairly small gap between the 9 mg and 12 mg groups in most GI categories suggests that GI effects stop climbing much at higher doses. If more TRIUMPH trials confirm this, it could guide dose choice.

Discontinuation Rates in TRIUMPH-4

TRIUMPH-4 enrolled 445 participants. Discontinuation due to adverse events rose with dose:

• Placebo: 4.0%
• Retatrutide 9 mg: 12.2%
• Retatrutide 12 mg: 18.2%

These rates broadly match Phase 2, where 16% of participants stopped because of adverse events at 12 mg. The rise to 18.2% in Phase 3 may reflect the longer treatment period. Lilly reported that discontinuation was lower in participants with a BMI of 35 or more (8.8% at 9 mg, 12.1% at 12 mg). In TRIUMPH-1, discontinuation due to adverse events at 12 mg was 11.3% (placebo 4.9%).

Non-GI Side Effects

Injection Site Reactions

Retatrutide is given as an injection under the skin. In the Phase 2 obesity trial, injection-site reactions were reported in 8% of the 12 mg group, 0% to 3% of the other retatrutide groups and none on placebo:

• Injection site erythema (redness): mild, transient
• Injection site pain: generally rated as minimal
• Injection site pruritus (itching): uncommon
• Injection site induration (hardness): rare

No anaphylactic or severe hypersensitivity reactions were reported. Retatrutide triggers little immune response: only a small share of participants developed anti-drug antibodies, and these did not affect efficacy. That supports the tolerability of the injection route.

Heart Rate Changes

Like GLP-1 receptor agonists, retatrutide raises heart rate. In the Phase 2 obesity trial, heart rate rose with dose, peaked at 24 weeks and declined at 36 and 48 weeks. The authors noted that both glucagon and GLP-1 can speed the heart and described the increases as similar to those reported for GLP-1 receptor agonists. The main text of the paper does not give the size of the rise; the figures are in supplementary tables we have not been able to check. Cardiac arrhythmia events (mostly supraventricular arrhythmias and conduction disorders) were reported in 11% of the 12 mg group and 3% on placebo.

Agent	Mean heart rate increase (source)
Retatrutide	Rose with dose, peaked at week 24, then declined (Phase 2; size not given in the main paper)
Semaglutide 2.4 mg (Wegovy)	1 to 4 bpm more than placebo (US label)
Tirzepatide (Zepbound)	1 to 3 bpm, no increase on placebo (US label)

How much this rise matters clinically is still debated, but it came alongside large improvements in blood pressure and metabolic measures.

Hypoglycemia

In the obesity trial, where participants did not have diabetes, no clinically significant hypoglycemia was seen. In the type 2 diabetes trial, hypoglycemia rates were low and were linked to sulfonylureas or insulin taken at the same time rather than to retatrutide itself. Because GLP-1 and GIP receptors only boost insulin release when glucose is high, they have a built-in guard against hypoglycemia, and the glucagon component adds protection by prompting the liver to release glucose when blood sugar falls.

Discontinuation Rates

Discontinuation due to adverse events is a key measure of how well a drug is tolerated in practice. In the Phase 2 obesity trial:

Dose Group	Discontinuation Rate
Placebo	0%
1 mg	7%
4 mg (2 mg start)	6%
4 mg (4 mg start)	9%
8 mg (2 mg start)	14%
8 mg (4 mg start)	6%
12 mg (2 mg start)	16%

The highest rate was at 12 mg, but the pattern across the smaller arms is uneven. At 12 mg, 84% of participants did not stop because of side effects.

For the Phase 2 type 2 diabetes trial, the published abstract reports that GI adverse events occurred in 35% of retatrutide participants (from 13% at 0.5 mg to 50% in the 8 mg fast-escalation group), 13% on placebo and 35% on dulaglutide 1.5 mg. It does not give a rate of stopping because of side effects.

How Retatrutide Side Effects Compare to Other GLP-1 Drugs

Patients and clinicians often ask how retatrutide’s tolerability compares with approved treatments. Cross-trial comparisons have limits, but the available data give useful context:

Adverse Event	Retatrutide 12 mg (TRIUMPH-4, 68 weeks)	Semaglutide 2.4 mg (Wegovy US label)	Tirzepatide 15 mg (Zepbound US label)
Nausea	43.2%	44%	28%
Vomiting	20.9%	24%	13%
Diarrhea	33.1%	30%	23%
Constipation	25.0%	24%	11%
Dysesthesia	20.9%	Not listed	Not listed
Heart rate increase	Rose with dose (size not given in the Phase 2 paper)	1 to 4 bpm vs placebo	1 to 3 bpm
Discontinuation due to AEs	18.2%	6.8%	6.7%

Key points:

• GI rates with retatrutide 12 mg are close to semaglutide 2.4 mg in these figures (nausea 43.2% vs 44%, diarrhea 33.1% vs 30%), and higher than tirzepatide 15 mg in every category.
• Discontinuation was higher with retatrutide (18.2% at 12 mg in TRIUMPH-4, 11.3% in TRIUMPH-1) than the 6.8% and 6.7% in the semaglutide and tirzepatide labels.
• Dysesthesia is unique to retatrutide among these drugs and is a distinct safety consideration.

Long-Term Safety Unknowns

Limitations of Current Data

This page draws mainly on Phase 2 trials (several hundred participants, up to 48 weeks) and TRIUMPH-4 (445 participants, 68 weeks); the later Phase 3 trials ran for 80 weeks in several thousand participants. Important limitations include:

• Sample size: Individual trials may be too small to detect uncommon adverse events that occur in <1% of patients. Rare but potentially serious effects may only show up in pooled analyses or post-marketing surveillance.
• Duration: 80 weeks is shorter than the expected length of chronic weight management treatment. Side effects that appear only with years of use cannot be judged from current data.
• Population diversity: Trial participants are chosen using strict criteria. The side effect profile in wider populations, including older adults, people with significant kidney or liver impairment, and patients on several other medicines, has not been fully mapped.
• Glucagon receptor unknowns: The long-term effects of ongoing glucagon receptor activation on liver function, bone metabolism and amino acid balance are not well understood in humans.

Specific Long-Term Concerns

Several areas need long-term monitoring as the program progresses:

• Thyroid C-cell tumors: GLP-1 receptor agonists carry a boxed warning about medullary thyroid carcinoma risk based on rodent data. Whether retatrutide carries similar or different risk is not yet established.
• Pancreatitis: An ongoing concern with all incretin-based drugs. Phase 2 data did not show higher pancreatitis rates, but larger and longer studies are needed.
• Gallbladder events: Rapid weight loss with GLP-1 agonists has been linked to more gallstones. This risk likely applies to retatrutide, given how much weight people lose.
• Lean mass preservation: Whether the glucagon component affects muscle loss during weight loss is an important question being studied in Phase 3 trials.
• Dysesthesia progression: Whether the sensory disturbance is temporary, progressive or reversible after stopping is unknown.

Phase 3 TRIUMPH Program

The Phase 3 TRIUMPH program, whose pivotal trials have now reported, greatly expands the safety database for retatrutide. With thousands of participants across several trials, it provides:

• Greater statistical power to detect uncommon adverse events
• Longer treatment durations for assessing chronic tolerability
• Data from more diverse patient populations
• Characterization of the dysesthesia signal across multiple trials and populations

Results from these trials will be the main basis for the regulatory safety review.

Managing Side Effects: Practical Guidance

Retatrutide is not yet approved, but trial experience suggests ways to manage side effects that may carry over into future practice:

For GI Side Effects

• Follow the dose-escalation protocol: Gradual dose titration is the single most effective way to limit GI side effects. In the trials, starting at 2 mg and increasing every 4 weeks let the body adapt.
• Dietary modifications: Smaller, more frequent meals, avoiding high-fat or spicy foods, and staying hydrated can reduce nausea and other GI symptoms.
• Timing of meals: Eating slowly and not lying down right after meals may help cut nausea.
• Anti-emetic medications: In clinical trials, investigators could prescribe anti-nausea medicines as needed for participants with moderate GI symptoms.

For Injection Site Reactions

• Rotate injection sites: Switching between abdomen, thigh and upper arm reduces local irritation.
• Allow alcohol prep to dry: Making sure the skin is fully dry before injecting reduces stinging.
• Room temperature medication: Letting the pen reach room temperature before injecting can reduce discomfort.

For Dysesthesia

There is no established way to manage the dysesthesia signal seen in TRIUMPH-4 yet, because it is a new finding. The full Phase 3 publications should show whether dysesthesia is temporary (clears on its own), dose-dependent (improves with a lower dose) or persistent. Trial participants with significant sensory symptoms should report them to their study team.

Summary

Across Phase 2 and Phase 3 trials, retatrutide’s side effects are broadly what you would expect from an incretin-based drug, with one notable exception. Gastrointestinal events, mainly nausea, vomiting and diarrhea, are the most common side effects. They rise with dose and cluster in the early dose-escalation period. Gradual dose titration makes the drug much easier to tolerate. Injection site reactions are uncommon and mild.

The TRIUMPH-4 Phase 3 trial identified dysesthesia as a new safety signal, affecting about 21% of participants at the 12 mg dose. This sensory disturbance is unique among incretin-based drugs and needs more study.

Discontinuation rises with dose but stays within an acceptable range, especially given the size of the benefit (-28.7% weight loss at 12 mg in TRIUMPH-4). Compared across trials with other GLP-1 drugs, retatrutide’s GI event rates in TRIUMPH-4 look similar to semaglutide 2.4 mg and higher than tirzepatide 15 mg, and its discontinuation rates are higher.

The full Phase 3 publications will provide the larger safety dataset needed for a complete benefit-risk assessment. Until then, the findings point to side effects that are generally manageable and support continued development, with dysesthesia as an important area for further study.